Craig Wilen

Dr. Craig Wilen

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2016 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
JDJohn G Doench
John G Doench
NFNicolo Fusi
Nicolo Fusi
MSMeagan Sullender
Meagan Sullender
MHMudra Hegde
Mudra Hegde
EVEmma W Vaimberg
Emma W Vaimberg
DRDavid E Root
David E Root
Genome-wide sgRNA libraries based on rules for on-target activity improve results of Cas9-based screens and facilitate a further refinement of on- and off-target prediction algorithms. CRISPR-Cas9–based genetic screens are a powerful new tool in biology. By simply altering the sequence of the single-guide RNA (sgRNA), one can reprogram Cas9 to target different sites in the genome with relative ease, but the on-target activity and off-target effects of individual sgRNAs can vary widely. Here, we use recently devised sgRNA design rules to create human and mouse genome-wide libraries, perform positive and negative selection screens and observe that the use of these rules produced improved results. Additionally, we profile the off-target activity of thousands of sgRNAs and develop a metric to predict off-target sites. We incorporate these findings from large-scale, empirical data to improve our computational design rules and create optimized sgRNA libraries that maximize on-target activity and minimize off-target effects to enable more effective and efficient genetic screens and genome engineering.

12 January 2021 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
ESEric Song
Eric Song
CZCe Zhang
Ce Zhang
BIBenjamin Israelow
Benjamin Israelow
ALAlice Lu-Culligan
Alice Lu-Culligan
APAlba Vieites Prado
Alba Vieites Prado
AIAkiko Iwasaki
Akiko Iwasaki
Although COVID-19 is considered to be primarily a respiratory disease, SARS-CoV-2 affects multiple organ systems including the central nervous system (CNS). Yet, there is no consensus on the consequences of CNS infections. Here, we used three independent approaches to probe the capacity of SARS-CoV-2 to infect the brain. First, using human brain organoids, we observed clear evidence of infection with accompanying metabolic changes in infected and neighboring neurons. However, no evidence for type I interferon responses was detected. We demonstrate that neuronal infection can be prevented by blocking ACE2 with antibodies or by administering cerebrospinal fluid from a COVID-19 patient. Second, using mice overexpressing human ACE2, we demonstrate SARS-CoV-2 neuroinvasion in vivo. Finally, in autopsies from patients who died of COVID-19, we detect SARS-CoV-2 in cortical neurons and note pathological features associated with infection with minimal immune cell infiltrates. These results provide evidence for the neuroinvasive capacity of SARS-CoV-2 and an unexpected consequence of direct infection of neurons by SARS-CoV-2.

10 April 2012 in Cold Spring Harbor Perspectives in Medicine
Verified
Journal Article
Open access
PDF file
CWCraig Wilen
Craig Wilen
JTJohn C. Tilton
John C. Tilton
RDRobert W. Doms
Robert W. Doms
The first step of the human immunodeficiency virus (HIV) replication cycle—binding and entry into the host cell—plays a major role in determining viral tropism and the ability of HIV to degrade the human immune system. HIV uses a complex series of steps to deliver its genome into the host cell cytoplasm while simultaneously evading the host immune response. To infect cells, the HIV protein envelope (Env) binds to the primary cellular receptor CD4 and then to a cellular coreceptor. This sequential binding triggers fusion of the viral and host cell membranes, initiating infection. Revealing the mechanism of HIV entry has profound implications for viral tropism, transmission, pathogenesis, and therapeutic intervention. Here, we provide an overview into the mechanism of HIV entry, provide historical context to key discoveries, discuss recent advances, and speculate on future directions in the field.

28 April 2022 in Nature
Verified
Journal Article
Open access
PDF file
ESEsen Sefik
Esen Sefik
RQRihao Qu
Rihao Qu
CJCaroline Junqueira
Caroline Junqueira
EKEleanna Kaffe
Eleanna Kaffe
HMHaris Mirza
Haris Mirza
RFRichard A. Flavell
Richard A. Flavell
Severe COVID-19 is characterized by persistent lung inflammation, inflammatory cytokine production, viral RNA and a sustained interferon (IFN) response, all of which are recapitulated and required for pathology in the SARS-CoV-2-infected MISTRG6-hACE2 humanized mouse model of COVID-19, which has a human immune system1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20. Blocking either viral replication with remdesivir21,22,23 or the downstream IFN-stimulated cascade with anti-IFNAR2 antibodies in vivo in the chronic stages of disease attenuates the overactive immune inflammatory response, especially inflammatory macrophages. Here we show that SARS-CoV-2 infection and replication in lung-resident human macrophages is a critical driver of disease. In response to infection mediated by CD16 and ACE2 receptors, human macrophages activate inflammasomes, release interleukin 1 (IL-1) and IL-18, and undergo pyroptosis, thereby contributing to the hyperinflammatory state of the lungs. Inflammasome activation and the accompanying inflammatory response are necessary for lung inflammation, as inhibition of the NLRP3 inflammasome pathway reverses chronic lung pathology. Notably, this blockade of inflammasome activation leads to the release of infectious virus by the infected macrophages. Thus, inflammasomes oppose host infection by SARS-CoV-2 through the production of inflammatory cytokines and suicide by pyroptosis to prevent a productive viral cycle.

1 January 2021 in Cell
Verified
Journal Article
Closed access
JWJin Wei
Jin Wei
MAMia Madel Alfajaro
Mia Madel Alfajaro
PDPeter C. DeWeirdt
Peter C. DeWeirdt
RHRuth E. Hanna
Ruth E. Hanna
WLWilliam J. Lu-Culligan
William J. Lu-Culligan
CWCraig Wilen
Craig Wilen

29 March 2013 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
NPNicholas F. Parrish
Nicholas F. Parrish
FGFeng Gao
Feng Gao
HLHui Li
Hui Li
EGElena E. Giorgi
Elena E. Giorgi
HBHannah J. Barbian
Hannah J. Barbian
BHBeatrice Hahn
Beatrice Hahn
Defining the virus–host interactions responsible for HIV-1 transmission, including the phenotypic requirements of viruses capable of establishing de novo infections, could be important for AIDS vaccine development. Previous analyses have failed to identify phenotypic properties other than chemokine receptor 5 (CCR5) and CD4+ T-cell tropism that are preferentially associated with viral transmission. However, most of these studies were limited to examining envelope (Env) function in the context of pseudoviruses. Here, we generated infectious molecular clones of transmitted founder (TF; n = 27) and chronic control (CC; n = 14) viruses of subtypes B ( n = 18) and C ( n = 23) and compared their phenotypic properties in assays specifically designed to probe the earliest stages of HIV-1 infection. We found that TF virions were 1.7-fold more infectious ( P = 0.049) and contained 1.9-fold more Env per particle ( P = 0.048) compared with CC viruses. TF viruses were also captured by monocyte-derived dendritic cells 1.7-fold more efficiently ( P = 0.035) and more readily transferred to CD4+ T cells ( P = 0.025). In primary CD4+ T cells, TF and CC viruses replicated with comparable kinetics; however, when propagated in the presence of IFN-α, TF viruses replicated to higher titers than CC viruses. This difference was significant for subtype B ( P = 0.000013) but not subtype C ( P = 0.53) viruses, possibly reflecting demographic differences of the respective patient cohorts. Together, these data indicate that TF viruses are enriched for higher Env content, enhanced cell-free infectivity, improved dendritic cell interaction, and relative IFN-α resistance. These viral properties, which likely act in concert, should be considered in the development and testing of AIDS vaccines.